HLS Therapeutics Inc.
HLTRF
Price:
$2.5
Market Cap:
$79.48M
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; ...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2010-01-27
Stock Exchange
PNK
Ticker
HLTRF
PE Ratio
[-3.33]
ROE
[-26.13%]
Current Ratio
[2.02]
Dividend Yield
[0%]
Enterprise Value
[130.03M]
Dividend History
The ROE as of November 2024 (TTM) for HLS Therapeutics Inc. (HLTRF) is -26.13%
According to HLS Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is -26.13%. This represents a change of 299.02% compared to the average of -6.55% of the last 4 quarters.
HLS Therapeutics Inc. (HLTRF) Historical ROE (quarterly & annually)
How has HLTRF ROE performed in the past?
The mean historical ROE of HLS Therapeutics Inc. over the last ten years is -7.79%. The current -26.13% ROE has changed 235.58% with respect to the historical average. Over the past ten years (40 quarters), HLTRF's ROE was at its highest in in the December 2014 quarter at 11.00%. The ROE was at its lowest in in the September 2018 quarter at -11.83%.
Average
-7.79%
Median
-8.61%
Minimum
-28.84%
Maximum
27.20%
HLS Therapeutics Inc. (HLTRF) ROE by Quarter and Year
Discovering the peaks and valleys of HLS Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 363.06%
Maximum Annual ROE = 27.20%
Minimum Annual Increase = -124.47%
Minimum Annual ROE = -28.84%
| Year | ROE | Change |
|---|---|---|
| 2023 | -28.84% | 53.18% |
| 2022 | -18.83% | 130.75% |
| 2021 | -8.16% | -9.91% |
| 2020 | -9.06% | -17.44% |
| 2019 | -10.97% | -29.90% |
| 2018 | -15.65% | 363.06% |
| 2017 | -3.38% | -3.53% |
| 2016 | -3.50% | -47.36% |
| 2015 | -6.66% | -124.47% |
| 2014 | 27.20% | 13.27% |
HLS Therapeutics Inc. (HLTRF) Average ROE
How has HLTRF ROE performed in the past?
The current ROE of HLS Therapeutics Inc. (HLTRF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-18.61%
5-year avg
-15.17%
10-year avg
-7.79%
HLS Therapeutics Inc. (HLTRF) ROE vs. Peers
How is HLTRF’s ROE compared to its peers?
HLS Therapeutics Inc.’s ROE is less than Aion Therapeutic Inc. (60.85%), less than Cipher Pharmaceuticals Inc. (27.24%), less than Cannara Biotech Inc. (6.59%), greater than Knight Therapeutics Inc. (-2.75%), greater than Canntab Therapeutics Limited (-376.92%), less than Bionoid Pharma Inc. (33.29%), greater than Crescita Therapeutics Inc. (-16.29%), less than CENTR Brands Corp. (288.28%), less than RAMM Pharma Corp. (0%), greater than Craftport Cannabis Corp. (-194.22%), greater than Speakeasy Cannabis Club Ltd. (-16.76%), less than City View Green Holdings Inc. (65.45%), greater than RavenQuest BioMed Inc. (-203.42%), greater than Lowell Farms Inc. (-287.32%),
| Company | ROE | Market cap |
|---|---|---|
| 60.85% | $2.39M | |
| 27.24% | $279.69M | |
| 6.59% | $48.02M | |
| -2.75% | $407.94M | |
| -376.92% | $147.02K | |
| 33.29% | $12.19M | |
| -16.29% | $8.61M | |
| 288.28% | $3.47M | |
| 0% | $15.16M | |
| -194.22% | $6.48B | |
| -16.76% | $1.31K | |
| 65.45% | $1.92M | |
| -203.42% | $482.11K | |
| -287.32% | $292.10K |
Build a custom stock screener for HLS Therapeutics Inc. (HLTRF) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like HLS Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
HLS Therapeutics Inc. (HLTRF) and other stocks custom spreadsheet templates
The easiest way to analyze a company like HLS Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is HLS Therapeutics Inc.'s ROE?
How is the ROE calculated for HLS Therapeutics Inc. (HLTRF)?
What is the highest ROE for HLS Therapeutics Inc. (HLTRF)?
What is the 3-year average ROE for HLS Therapeutics Inc. (HLTRF)?
What is the 5-year average ROE for HLS Therapeutics Inc. (HLTRF)?
How does the current ROE for HLS Therapeutics Inc. (HLTRF) compare to its historical average?